The Relevance of Continuous Solid Oral Dosage Processing and NIR Spectroscopy In Meeting the Needs of QbD and PAT - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relevance of Continuous Solid Oral Dosage Processing and NIR Spectroscopy In Meeting the Needs of QbD and PAT
The author discusses control strategies via near infrared instrumentation for continuous mixing, granulation, drying, and extrusion with a more focused detail on mixing.


Pharmaceutical Technology
Volume 33, Issue 10, pp. 112-120

References

1. FDA, "Pharmaceutical CGMPs for the 21st Century: A Risk-Based Approach," (Rockville, MD, Aug. 2002).

2. K. Stryczek et al., "Capitalizing on Aggregate Data for Gaining Process Understanding-Effect of Raw Material, Environmental and Process Conditions on the Dissolution Rate of a Sustained Release Product," J. Pharm. Innov. 2 (1–2), 6–17 (2007).

3. FDA, Draft Guidance for Industry, Process Validation: General Principles and Practices (Rockville, MD, November 2008).

4. ISA, ANSI/ISA S95.00.03, Enterprise-Control System Integration-Part 3: Activity Models for Manufacturing Operation Management (Raleigh, NC, 2005).

5. J. Hirsch and T. Strother, "Lactose Particle Size Analysis Using FT-NIR Spectroscopy," Application Note 51557, Thermo Fisher Scientific, Madison, WI (2007).

6. I. T. Cameron and F. Y. Wang, "Granulation Process Modeling," in the Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, Ed. (Taylor & Francis, Boca Raton, FL, 2nd ed), pp. 555–590 (2005).

7. R. P. Cogdill et al., "The Financial Returns on Investment in Process Analytical Technology and Lean Manufacturing: Benchmarks and Case Study," J. Pharm. Innov. 2 (1–2), 38–50 (2007).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here